1. Home
  2. PHGE vs CXAI Comparison

PHGE vs CXAI Comparison

Compare PHGE & CXAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHGE
  • CXAI
  • Stock Information
  • Founded
  • PHGE 2015
  • CXAI N/A
  • Country
  • PHGE Israel
  • CXAI United States
  • Employees
  • PHGE N/A
  • CXAI N/A
  • Industry
  • PHGE Biotechnology: Pharmaceutical Preparations
  • CXAI EDP Services
  • Sector
  • PHGE Health Care
  • CXAI Technology
  • Exchange
  • PHGE Nasdaq
  • CXAI Nasdaq
  • Market Cap
  • PHGE 26.5M
  • CXAI 26.7M
  • IPO Year
  • PHGE N/A
  • CXAI N/A
  • Fundamental
  • Price
  • PHGE $0.49
  • CXAI $1.35
  • Analyst Decision
  • PHGE Strong Buy
  • CXAI
  • Analyst Count
  • PHGE 2
  • CXAI 0
  • Target Price
  • PHGE $22.50
  • CXAI N/A
  • AVG Volume (30 Days)
  • PHGE 159.9K
  • CXAI 526.6K
  • Earning Date
  • PHGE 11-14-2024
  • CXAI 11-12-2024
  • Dividend Yield
  • PHGE N/A
  • CXAI N/A
  • EPS Growth
  • PHGE N/A
  • CXAI N/A
  • EPS
  • PHGE N/A
  • CXAI N/A
  • Revenue
  • PHGE N/A
  • CXAI $7,200,000.00
  • Revenue This Year
  • PHGE N/A
  • CXAI $8.01
  • Revenue Next Year
  • PHGE N/A
  • CXAI $92.31
  • P/E Ratio
  • PHGE N/A
  • CXAI N/A
  • Revenue Growth
  • PHGE N/A
  • CXAI N/A
  • 52 Week Low
  • PHGE $0.49
  • CXAI $1.03
  • 52 Week High
  • PHGE $8.55
  • CXAI $7.07
  • Technical
  • Relative Strength Index (RSI)
  • PHGE 21.78
  • CXAI 41.97
  • Support Level
  • PHGE $0.56
  • CXAI $1.24
  • Resistance Level
  • PHGE $0.79
  • CXAI $1.48
  • Average True Range (ATR)
  • PHGE 0.10
  • CXAI 0.15
  • MACD
  • PHGE -0.02
  • CXAI -0.01
  • Stochastic Oscillator
  • PHGE 0.00
  • CXAI 14.10

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

About CXAI CXApp Inc.

CXApp Inc is a workplace experience platform for enterprise customers. It is a SaaS product for enterprise organizations, distributing a mobile app to all employees within the organization. It includes a content management system (or CMS) so customers can adjust configurations for their workplace settings autonomously and spontaneously. Its technologies and solutions help enterprise customers deliver a comprehensive business journey in a work 'from anywhere' world for employees, partners, customers, and visitors. CXApp offers native mapping, analytics, on-device positioning (or ODP), and application technologies that bring people together.

Share on Social Networks: